Trial Profile
Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2020
Price :
$35
*
At a glance
- Drugs Dacarbazine (Primary) ; Sorafenib (Primary)
- Indications Leiomyosarcoma; Nerve sheath neoplasms; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 13 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jan 2013 Planned End Date changed from 1 Feb 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 27 Jan 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.